IVERIC bio Inc (ISEE) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ISEE • US46583P1021

39.95 USD
+0.15 (+0.38%)
At close: Jul 10, 2023
39.94 USD
-0.01 (-0.03%)
After Hours: 7/10/2023, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall ISEE gets a fundamental rating of 2 out of 10. We evaluated ISEE against 523 industry peers in the Biotechnology industry. The financial health of ISEE is average, but there are quite some concerns on its profitability. ISEE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ISEE had negative earnings in the past year.
  • ISEE had a negative operating cash flow in the past year.
ISEE Yearly Net Income VS EBIT VS OCF VS FCFISEE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

1.2 Ratios

  • ISEE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISEE Yearly ROA, ROE, ROICISEE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 200 300

1.3 Margins

  • ISEE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISEE Yearly Profit, Operating, Gross MarginsISEE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ISEE has more shares outstanding than it did 1 year ago.
  • ISEE has a worse debt/assets ratio than last year.
ISEE Yearly Shares OutstandingISEE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
ISEE Yearly Total Debt VS Total AssetsISEE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • ISEE has an Altman-Z score of 22.00. This indicates that ISEE is financially healthy and has little risk of bankruptcy at the moment.
  • ISEE's Altman-Z score of 22.00 is amongst the best of the industry. ISEE outperforms 94.41% of its industry peers.
  • A Debt/Equity ratio of 0.20 indicates that ISEE is not too dependend on debt financing.
  • ISEE's Debt to Equity ratio of 0.20 is on the low side compared to the rest of the industry. ISEE is outperformed by 69.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 22
ROIC/WACCN/A
WACCN/A
ISEE Yearly LT Debt VS Equity VS FCFISEE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M 400M

2.3 Liquidity

  • ISEE has a Current Ratio of 15.53. This indicates that ISEE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 15.53, ISEE belongs to the best of the industry, outperforming 87.97% of the companies in the same industry.
  • ISEE has a Quick Ratio of 15.53. This indicates that ISEE is financially healthy and has no problem in meeting its short term obligations.
  • ISEE's Quick ratio of 15.53 is amongst the best of the industry. ISEE outperforms 87.97% of its industry peers.
Industry RankSector Rank
Current Ratio 15.53
Quick Ratio 15.53
ISEE Yearly Current Assets VS Current LiabilitesISEE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ISEE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -55.75%.
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ISEE will show a very strong growth in Earnings Per Share. The EPS will grow by 33.86% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISEE Yearly Revenue VS EstimatesISEE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
ISEE Yearly EPS VS EstimatesISEE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ISEE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISEE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISEE Price Earnings VS Forward Price EarningsISEE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISEE Per share dataISEE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • ISEE's earnings are expected to grow with 25.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.29%
EPS Next 3Y25.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ISEE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IVERIC bio Inc

NASDAQ:ISEE (7/10/2023, 8:00:03 PM)

After market: 39.94 -0.01 (-0.03%)

39.95

+0.15 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10
Earnings (Next)07-24
Inst Owners0.92%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change0%
Market Cap5.51B
Revenue(TTM)N/A
Net Income(TTM)-222.90M
Analysts52.86
Price Target39.88 (-0.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.08%
Min EPS beat(2)-22.88%
Max EPS beat(2)-11.29%
EPS beat(4)1
Avg EPS beat(4)-11.73%
Min EPS beat(4)-27.83%
Max EPS beat(4)15.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.38%
PT rev (3m)25.45%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-2.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.55
P/tB 11.55
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS3.46
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 456.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.53
Quick Ratio 15.53
Altman-Z 22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.94%
EBIT Next 3Y31.5%
EBIT Next 5Y39.62%
FCF growth 1Y-127.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.44%
OCF growth 3YN/A
OCF growth 5YN/A

IVERIC bio Inc / ISEE FAQ

What is the ChartMill fundamental rating of IVERIC bio Inc (ISEE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ISEE.


Can you provide the valuation status for IVERIC bio Inc?

ChartMill assigns a valuation rating of 1 / 10 to IVERIC bio Inc (ISEE). This can be considered as Overvalued.


How profitable is IVERIC bio Inc (ISEE) stock?

IVERIC bio Inc (ISEE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ISEE stock?

The Earnings per Share (EPS) of IVERIC bio Inc (ISEE) is expected to decline by -21.05% in the next year.